Stereochemistry | ACHIRAL |
Molecular Formula | C4H9NO |
Molecular Weight | 87.1204 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(C)=O
InChI
InChIKey=FXHOOIRPVKKKFG-UHFFFAOYSA-N
InChI=1S/C4H9NO/c1-4(6)5(2)3/h1-3H3
N,N-Dimethylacetamide (DMA) is a multipurpose reagent which delivers its own H, C, N and O atoms for the synthesis of a variety of compounds under a number of different experimental conditions. N,N-Dimethylacetamide is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. It has been shown that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. DMA has a potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. N,N-Dimethylacetamide is used as a polar solvent in organic synthesis as well as in reactions involving strong bases such as sodium hydroxide. N,N-Dimethylacetamide finds application as a reaction medium in the production of pharmaceuticals, agrochemicals, dyes and plasticizers. It is widely used in polymer industry due to its high solving power for high molecular-weight polymers and synthetic resins. It plays an important role as a catalyst in various reactions viz. cyclization, halogenation, cynidation, alkylation and dehydrogenation and increases the yield of main products. It is also used as an extracting agent for oil and gases, in paint removers, in the production of photo-resist stripping compounds and as booster solvent in coatings.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Inactive ingredient |
Doses
AEs
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Tox targets
PubMed
Patents
Sample Use Guides
Rats: N,N-Dimethylacetamide (DMA) was administered once a week via i.p. injections (92 ul DMA plus 108 ul PBS per 100 gr. rat).
Route of Administration:
Intraperitoneal
N,N-Dimethylacetamide (DMA) inhibits the binding activity of BRD2 and BRD4 with an IC50 value of 11 mM and 6 mM, respectively. RAW264.7 cells were seeded on a 24-well culture plate and treated with RANKL alone or with different concentrations of DMA (1.25 mM, 2.5 mM, 5mM). After 6 days of incubation, TRAP activity was measured.